S. 2336

119 S2336 IS: Halting the Epidemic of Addiction and Loss Act of 2025
 U.S. Senate
 2025-07-17
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
  II
  119th CONGRESS
  1st Session
  S. 2336
  IN THE SENATE OF THE UNITED STATES
  July 17, 2025
  Mr. Cornyn  (for himself and  Ms. Hassan ) introduced the following bill; which was
  read twice and referred to the  Committee on
  Health, Education, Labor, and Pensions
  A BILL
To ensure references to opioid overdose reversal agents in certain grant
  programs of the Department of Health and Human Services are not limited to
  naloxone.
1.
Short title
This Act may be cited as the   Halting the Epidemic of Addiction and Loss Act of 2025  .
2.
References to opioid overdose reversal agents in HHS grant programs
(a)
In general
The Secretary of Health and Human Services shall ensure that, as appropriate, whenever the Department of Health and Human Services issues a regulation or guidance for any grant program addressing opioid misuse and use disorders, any reference to an opioid overdose reversal drug (such as a reference to naloxone) is inclusive of any opioid overdose reversal drug that has been approved under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) for emergency treatment of a known or suspected opioid overdose.
(b)
Existing references
(1)
Update
Not later than one year after the date of enactment of this Act, the Secretary of Health and Human Services shall update all references described in paragraph (2) to be inclusive of any opioid overdose reversal drug that has been approved or otherwise authorized for use by the Food and Drug Administration.
(2)
References
A reference described in this paragraph is any reference to an opioid overdose reversal drug (such as naloxone) in any regulation or guidance of the Department of Health and Human Services that—
(A)
was issued before the date of enactment of this Act; and
(B)
is included in—
(i)
the grant program for State and Tribal response to opioid use disorders under section 1003 of the 21st Century Cures Act ( 42 U.S.C. 290ee–3a ) (commonly referred to as  State Opioid Response Grants  and  Tribal Opioid Response Grants ); or
(ii)
the grant program for priority substance use disorder prevention needs of regional and national significance under section 516 of the Public Health Service Act ( 42 U.S.C. 290bb–22 ).